MSACL 2019 US Abstract

Part I: Digest Optimization and Quality Control for Proteomic Assays

Timothy S. Collier
Quest Diagnostics - Cleveland HeartLab Cardiometabolic Center of Excellence, Ohio, USA

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Timothy Collier (Presenter) Quest Diagnostics - Cleveland HeartLab >> ADDL INFO (PDF)

Presenter Bio: Dr. Timothy Collier is an Associate Scientific Director for Quest Diagnostics - Cleveland HeartLab Cardiometabolic Center of Excellence, where he oversees the technical performance of laboratory operations. Previously as a Sr. R&D Scientist, his responsibilities included the identification and development of assays for cardiovascular biomarkers. Prior to joining Cleveland HeartLab, he was a Post-Doctoral Research Scholar in Molecular Oncology and Hematology at Washington University School of Medicine in St. Louis, MO, focusing on the identification of drug-resistance mechanisms and structural studies of cancer-driving mutations using quantitative mass spectrometry.

Relevant Financial Disclosures (within past 24 months) Committee/Board/Advisory Board MSACL Scientific Committee Stock/Bonds Quest Diagnostics Salary Quest Diagnostics Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

This practical training session consists of two parts, presented by Grace van der Gugten (St. Paul’s Hopital) and Tim Collier (Quest Diagnostics). Part I is an overview of one of the most common and key components of the pre-analytical workflow for absolute quantification of proteins by LC-MS/MS – enzymatic digestion. Here we will present a typical digestion workflow, discuss pre-digest sample treatment strategies, enzyme selection and digest condition optimization. We will also discuss useful strategies for assessing assay performance during assay development and deployment. Following Part I, Part II and Part III will consist of real-world proteomic assay case discussions.